SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.
SK bioscience signed a licensing deal with Novavax to be one of the manufacturers of the U.S. pharmaceutical company’s Covid-19 vaccine targeting Omicron variants.
Korea will begin administering Novavax’s Covid-19 vaccine next week to unvaccinated people over 18 and people at higher risk of severe illness and death.
SK Bioscience is the most likeliest to first introduce a Korean vaccine as it is the only company that has completed phase 3 clinical trials.
Covid-19 pills will start being prescribed Friday to patients with weak immune systems and people over 64.
President Moon Jae-in met Novavax CEO Stanley Erck on Tuesday but revealed little about when its vaccines may be ready for Korea.
President Moon Jae-in announced his confidence surrounding Covid-19 vaccine supplies as the country plans to produce 20 million Novavax doses by the third quarter.
Korea signed separate deals for vaccines from U.S. pharmaceutical companies Novavax and Pfizer to inoculate an additional 23 million people, Prime Minister Chung Sye-kyun announced Tuesday.
Prime Minister Chung Sye-kyun said Wednesday that Korea's first batch of Covid-19 vaccines will probably be enough to inoculate 50,000 people.
Korea JoongAng Daily Sitemap
